BMRN - belongs to the medical industry.
Biomarine is an American biotechnology company focused on enzyme replacement therapy.
On August 1, it reported financial results for the second quarter of 2019. Revenue for the quarter was $ 387.8 million, up 4% from $ 372.8 million for the same period last year. The net loss was $ 37.4 million, compared to a net loss of $ 16.8 million in the same quarter last year.
Other points to consider:
All of the above, of course, at your own discretion, your trading rules and your preferred trading strategies.
This is not a recommendation to buy / sell.
Goodluck.
Biomarine is an American biotechnology company focused on enzyme replacement therapy.
On August 1, it reported financial results for the second quarter of 2019. Revenue for the quarter was $ 387.8 million, up 4% from $ 372.8 million for the same period last year. The net loss was $ 37.4 million, compared to a net loss of $ 16.8 million in the same quarter last year.
Other points to consider:
- Is in the lower Bollinger strip, you will probably fix.
Reversal candle..
Is at a significant level
All of the above, of course, at your own discretion, your trading rules and your preferred trading strategies.
This is not a recommendation to buy / sell.
Goodluck.
,The quieter you become
the more you can hear
(Ram Dass)
the more you can hear
(Ram Dass)